Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Immunology, Autoimmunity, and Autoantibodies in Parkinson’s Disease

Abstract

Recent revelations of immune alterations in Parkinson’s disease have led to the convergence that an autoimmune mechanism may play a role in the etiopathogenesis of this neurodegenerative disease. In the current study, 77 Parkinson’s disease patients and 77 matched healthy controls were analyzed for the presence of seven autoantibodies previously found to be associated with central nervous system manifestations namely: antineuronal-cells, anti-brain lysate, anti-dsDNA, anti-phosphatidylserine, anti-cardiolipin, anti-serotonin, and anti-melanocytes antibodies. Patients underwent systematic assessments of demographics, clinical, and biochemical manifestations. Three autoantibodies were found to be more prevalent among Parkinson’s disease patients (antineuronal cells10.3% vs. 1.3%, p = 0.017; anti-brain lysate 9.1% vs. 1.3%, p = 0.032; anti-dsDNA 10.3% vs. 2.6%, p = 0.049). Clinical manifestations of Parkinson’s disease, particularly dyskinesia and depression, were found to be associated with the presence of these autoantibodies.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Nussbaum RL, Ellis CE (2003) Alzheimer’s disease and Parkinson disease. N Engl J Med 348:1356–1364

  2. 2.

    Israel Z, Hassin-Bear S (2005) Subthalamic stimulation for Parkinson’s disease. IMAJ 7:458–463

  3. 3.

    Crossman AR (2000) Functional anatomy of movement disorders. J Anat 196:519–525

  4. 4.

    Lerler A, Bagic A (2008) Olfactory pathogenesis of idiopathic Parkinson disease revisited. Mov Disord 23:1076–1084

  5. 5.

    Benkler M, Agmon-Levin N, Shoenfeld Y (2009) Parkinson’s disease, autoimmunity, and olfaction. Int J Neurosci 119:2133–2143

  6. 6.

    Shoenfeld Y, Blank M, Abu-Shakra M et al (2008) The mosaic of autoimmunity: prediction, autoantibodies and therapy in autoimmune disease. IMAJ 10:13–19

  7. 7.

    Møller A, Perrild H, Pedersen H, Høier-Madsen M (1989) Parkinson’s disease and autoimmunity. Acta Neurol Scand 79:173–175

  8. 8.

    Liu B, Gao HM, Hong JS (2003) Parkinson’s disease and exposure to infectious agents and pesticides and the occurrence of brain injury: role of neuroinflammation. Environ Health Perspect 111:1065–1073

  9. 9.

    Fiszer U, Mix E, Fredrikson S, Kostulas V, Olsson T, Link H (1994) Gamma delta+T cells are increased in patients with Parkinson’s disease. J Neurol Sci 121:39–45

  10. 10.

    Papachroni KK, Ninkina N, Papapanagiotou A et al (2007) Autoantibodies to alpha-synuclein in inherited Parkinson’s disease. J Neurochem 101:749–756

  11. 11.

    Zappia M, Crescibene L, Bosco D et al (2002) Anti-GM1 ganglioside antibodies in Parkinson’s disease. Acta Neurol Scand 106:54–57

  12. 12.

    Carvey PM, McRae A, Lint TF et al (1991) The potential use of dopamine neuron antibody and a striatal-derived neurotropic factor as diagnostic markers in Parkinson’s disease. Neurology 41:53–58

  13. 13.

    Le WD, Rowe DB, Jankovic J, Xei W, Apple SH (1999) Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol 56:194–200

  14. 14.

    Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM (2005) A possible role of humoral immunity in the pathogenesis of Parkinson’s disease. Brain 128:2665–2674

  15. 15.

    Chen S, Le WD, Xie WJ et al (1998) Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch Neurol 55:1075–1080

  16. 16.

    He Y, Le WD, Appel SH (2002) Role of FCγ receptors in nigral cell injury induced by Parkinson’s disease immunoglobulin injection into mouse substantia nigra. Exp Neurol 176:322–327

  17. 17.

    Al-Fulaij MA, Ren Y, Beinborn M, Kopin AS (2008) Pharmacological analysis of human D1 and D2 dopamine receptor missense variants. J Mol Neurosci 34:211–223

  18. 18.

    Abramsky O, Litvin Y (1978) Autoimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson’s disease and schizophrenia. Perspect Biol Med 22:104–114

  19. 19.

    Luedtke RR, Griffin SA, Conroy SS, Jin X, Pinto A, Sesack SR (1999) Immunoblot and immunohistochemical comparison of murine monoclonal antibodies specific for the rat D1a and D1b dopamine receptor subtypes. J Neuroimmunol 101:170–187

  20. 20.

    Farooqui SM, Brock JW, Hamdi A, Prasad C (1991) Antibodies against synthetic peptides predicted from the nucleotide sequence of D2 receptor recognize native dopamine receptor protein in rat striatum. J Neurochem 57:1363–1369

  21. 21.

    Boundy VA, Luedtke RR, Artymyshyn RP, Filtz TM, Molinoff PB (1993) Development of polyclonal anti-D2 dopamine receptor antibodies using sequence-specific peptides. Mol Pharmacol 43:666–676

  22. 22.

    Johnston JM, Wood DF, James JD, Johanston DG (1992) Preparation and characterization of an antibody specific to the rat dopamine D2 receptor. J Endocrinol 134:227–233

  23. 23.

    Myers PR, Donlon M, McCarthy K, Livengood D, Shain W (1976) Evidence for a dopamine receptor antibody. Biochem Biophys Res Commun 72:1311–1318

  24. 24.

    Agmon-Levin N, Shaye K, Shoenfeld Y (2009) Neuropsychiatric manifestations of systemic lupus erythematosus—a primary disease manifestation. J Neuroimmunol 207:1–2

  25. 25.

    Gualtierotti R, Biggioggero M, Penatti AE, Meroni PL (2010) Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 10:3–7

  26. 26.

    Briani C, Lucchetta M, Ghirardello A et al (2009) Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study. J Autoimmun 32:79–84

  27. 27.

    Sakic B, Kirkham DL, Ballok DA et al (2005) Proliferating brain cells are a target of neurotoxic CSF in systemic autoimmune disease. J Neuroimmunol 169:68–85

  28. 28.

    Zandman-Goddard G, Chapman J, Shoenfeld Y (2007) Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 36:297–315

  29. 29.

    Tobón GJ, Alard JE, Youinou P, Jamin C (2009) Are autoantibodies triggering endothelial cell apoptosis really pathogenic? Autoimmun Rev 8:605–610

  30. 30.

    Zandman-Goddard G, Blank M, Langevitz P et al (2005) Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity. Ann Rheum Dis 64:1698–1702

  31. 31.

    Morer A, Lázaro L, Sabater L, Massana J, Castro J, Graus F (2008) Antineuronal antibodies in a group of children with obsessive—compulsive disorder and Tourette syndrome. J Psychiatr Res 42:64–68

  32. 32.

    Yeh CB, Wu CH, Tsung HC, Chen CW, Shyu JF, Leckman JF (2005) Antineural antibody in patients with Tourette’s syndrome and their family members. J Biomed Sci 13:101–112

  33. 33.

    Van de Warrenburg BP, Church AJ, Martino D et al (2008) Antineuronal antibodies in Parkinson’s disease. Mov Disord 23:958–963

  34. 34.

    Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184

  35. 35.

    WMA Medical Ethics Committee. Updating the WMA Declaration of Helsinki. Wld Med J 1999 45:11–13

  36. 36.

    York NR, Mendoza JP, Ortega SB et al (2010) Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis. J Autoimmun 35:33–44

  37. 37.

    Kotby AA, El Badawy N, El Sokkary S, Moawad H, El Shawarby M (1998) Antineuronal antibodies in rheumatic chorea. Clin Diagn Lab Immunol 5:836–839

  38. 38.

    Smith PP, Gordon C (2010) Systemic lupus erythematosus: clinical presentations. Autoimmun Rev 10:43–45

  39. 39.

    Hadjivassiliou M, Aeschlimann P, Strigun A, Sanders DS, Woodroofe N, Aeschlimann D (2008) Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. Ann Neurol 64:332–343

  40. 40.

    Hadjivassiliou M, Boscolo S, Tongiorgi E et al (2008) Cerebellar ataxia as a possible organ-specific autoimmune disease. Mov Disord 23:1370–1377

  41. 41.

    Katzav A, Ben-Ziv T, Chapman J, Blank M, Reichlin M, Shoenfeld Y (2008) Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS -SLE (depression). J Autoimmun 21:393–398

  42. 42.

    Agmon-Levin N, Gilburd B, Kivity S et al (2009) Anti-ribosomal-P antibodies in lupus patients and healthy controls: evaluation of three ELISA assays. IMAJ 11:403–406

  43. 43.

    Shoenfeld Y (2007) To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system. J Autoimmun 28:165–169

  44. 44.

    Katzav A, Solodeev I, Brodsky O et al (2007) Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheom 56:938–948

  45. 45.

    Toubi E, Shoenfeld Y (2007) Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev 6:119–125

  46. 46.

    Gao HX, Campbell SR, Cui MH et al (2009) Depression is an early disease manifestation in lupus-prone MRL/lpr mice. J Neuroimmunol 207:45–56

  47. 47.

    Moscavitch SD, Szyper-Kravitz M, Shoenfeld Y (2009) Autoimmune pathology accounts for common manifestations in a wide range of neuro-psychiatric disorders: the olfactory and immune system interrelationship. Clin Immunobiol 130:235–243

  48. 48.

    Fünfgeld EW, Baggen M, Nedwidek P, Richstein B, Mistlberger G (1989) Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer’s type (SDAT). Prog Clin Biol Res 317:1235–1246

Download references

Acknowledgments

This study was performed as part of the requirements for the M.D degree of the student Michal Benkler form the Medical school, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheba, Israel.

Author information

Correspondence to Yehuda Shoenfeld.

Additional information

Michal Benkler and Nancy Agmon-Levin contributed to the article equally.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Benkler, M., Agmon-Levin, N., Hassin-Baer, S. et al. Immunology, Autoimmunity, and Autoantibodies in Parkinson’s Disease. Clinic Rev Allerg Immunol 42, 164–171 (2012). https://doi.org/10.1007/s12016-010-8242-y

Download citation

Keywords

  • Parkinson’s disease
  • Autoimmune
  • Autoantibodies
  • Dyskinesia
  • Depression